Qianjiang Yongan Pharmaceutical Co Ltd Market Cap ($526.94 Million)
Market Cap & Net Worth: Qianjiang Yongan Pharmaceutical Co Ltd (002365)
Qianjiang Yongan Pharmaceutical Co Ltd market cap. Qianjiang Yongan Pharmaceutical Co Ltd (SHE:002365) has a market capitalization of $526.94 Million (CN¥3.60 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #11662 globally and #3271 in its home market, demonstrating a 10.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qianjiang Yongan Pharmaceutical Co Ltd's stock price CN¥12.22 by its total outstanding shares 294682500 (294.68 Million). Also see Qianjiang Yongan Pharmaceutical Co Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Qianjiang Yongan Pharmaceutical Co Ltd Market Cap History (2015–2026)
Qianjiang Yongan Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows growth from $580.93 Million to $526.94 Million (1.66% CAGR). Check 002365 stock price and chart for real-time trading data and today's change.
Qianjiang Yongan Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qianjiang Yongan Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Qianjiang Yongan Pharmaceutical Co Ltd (002365) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.41x
Qianjiang Yongan Pharmaceutical Co Ltd's market cap is 0.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.58x
Qianjiang Yongan Pharmaceutical Co Ltd's market cap is 5.58 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $580.93 Million | $555.89 Million | $17.61 Million | 1.05x | 32.98x |
| 2016 | $674.04 Million | $549.40 Million | $62.30 Million | 1.23x | 10.82x |
| 2017 | $893.69 Million | $932.77 Million | $133.15 Million | 0.96x | 6.71x |
| 2018 | $424.49 Million | $1.01 Billion | $178.58 Million | 0.42x | 2.38x |
| 2019 | $404.60 Million | $1.37 Billion | $89.93 Million | 0.30x | 4.50x |
| 2020 | $390.76 Million | $1.17 Billion | $105.56 Million | 0.33x | 3.70x |
| 2021 | $446.69 Million | $1.57 Billion | $111.42 Million | 0.29x | 4.01x |
| 2022 | $442.06 Million | $1.46 Billion | $140.35 Million | 0.30x | 3.15x |
| 2023 | $416.02 Million | $972.89 Million | -$12.31 Million | 0.43x | N/A |
| 2024 | $344.54 Million | $838.81 Million | $61.77 Million | 0.41x | 5.58x |
Competitor Companies of 002365 by Market Capitalization
Companies near Qianjiang Yongan Pharmaceutical Co Ltd in the global market cap rankings as of November 5, 2026. Also see 002365 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Qianjiang Yongan Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Qianjiang Yongan Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Qianjiang Yongan Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Qianjiang Yongan Pharmaceutical Co Ltd's market cap moved from $580.93 Million to $ 526.94 Million, with a yearly change of 1.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥526.94 Million | -18.10% |
| 2025 | CN¥643.37 Million | +86.73% |
| 2024 | CN¥344.54 Million | -17.18% |
| 2023 | CN¥416.02 Million | -5.89% |
| 2022 | CN¥442.06 Million | -1.04% |
| 2021 | CN¥446.69 Million | +14.31% |
| 2020 | CN¥390.76 Million | -3.42% |
| 2019 | CN¥404.60 Million | -4.68% |
| 2018 | CN¥424.49 Million | -52.50% |
| 2017 | CN¥893.69 Million | +32.59% |
| 2016 | CN¥674.04 Million | +16.03% |
| 2015 | CN¥580.93 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Qianjiang Yongan Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $526.94 Million USD |
| MoneyControl | $526.94 Million USD |
| MarketWatch | $526.94 Million USD |
| marketcap.company | $526.94 Million USD |
| Reuters | $526.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Qianjiang Yongan Pharmaceutical Co Ltd
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmace… Read more